<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078908</url>
  </required_header>
  <id_info>
    <org_study_id>JBR-1-2013</org_study_id>
    <secondary_id>2013-002211-10</secondary_id>
    <nct_id>NCT02078908</nct_id>
  </id_info>
  <brief_title>The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Healthy Humans. A Dose-response Study</brief_title>
  <official_title>The Effect of Sodium Nitrite on Renal Variables, Brachial and Central Blood Pressure in Healthy Humans. A Randomized, Cross Over, Placebo Controlled Dose-response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erling Bjerregaard Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of different doses of sodium nitrite
      infusion in 12 healthy subjects. The effects on renal handling of nitrite, nitrate, sodium
      and water, plasma concentrations of vasoactive hormones, peripheral (brachial) and central
      blood pressure will be evaluated.

      Hypothesis

      Sodium nitrite infusion

        1. increases urinary sodium excretion and renal filtration rate

        2. lowers blood pressure, central as well as peripheral

        3. affects vasoactive hormones

        4. it is possible to establish a dose that affects the renal function with only minor
           effect on the blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Nitric oxide (NO) is an important vasodilating molecule with a very complex biochemistry and
      metabolism. NO is classically synthesized from L-arginin by endothelial nitric oxide synthase
      (eNOS) located in the endothelial cell lining. Several chronic cardiovascular diseases such
      as hypertension, chronic kidney disease and diabetes are accompanied by endothelial
      dysfunction and hence diminished synthesis of NO. NO is a very reactive molecule and direct
      investigation of its function are limited and it has mainly been investigated by inhibition
      of eNOS. Recent research has shown that sodium nitrite is readily converted to NO by enzymes
      in vivo. The effects of sodium nitrite on renal variables, vasoactive hormones and central
      blood pressure are previously unexamined. It is now possible to achieve serial estimations of
      the central aortic systolic pressure (CASP) by newly designed wrist born device.

      Hypothesis:

        1. Sodium nitrite infusion increases the urinary sodium excretion and glomerular filtration
           rate (GFR) in a dose related manner.

        2. Sodium nitrite infusion increases plasma levels of nitrite, nitrate, NO and cyclic
           guanosine monophosphate (cGMP)

        3. Sodium nitrite infusion lowers the peripheral and central blood pressure

        4. Renal clearance of nitrite is constant and not dose dependent

        5. Sodium nitrite infusion affects vasoactive hormones

        6. It is possible to establish a dose that affects the renal variables with only minor
           effect on the blood pressure.

      Purpose:

      The purpose of this study is to investigate the effects of sodium nitrite infusion on

        1. Renal handling of nitrite, nitrate, sodium and water

        2. Plasma concentrations of vasoactive hormones

        3. Peripheral (brachial) blood pressure and CASP

      Design:

      12 healthy subjects are recruited in this randomised, cross over, placebo controlled,
      single-blinded study. Each subject will attend to four examination days. Four days prior to
      each examination day subjects are given a standardized diet with a low level of nitrate and
      nitrite. On the evening before the examination day the subjects take a single dose of lithium
      carbonate 300 mg in order to measure lithium clearance. On the examination days subjects are
      receiving a two hour infusion of either placebo (isotonic sodium chloride) or one of three
      doses of sodium nitrite. During the four examination days each subject receives all
      treatments in random order.

      Perspectives:

      Knowledge regarding hemodynamic and renal dose-response relationship is essential, in order
      to carry out future planned studies of the nitrite-NO system, in hypertensive subjects and
      during simultaneous modulation of various enzyme systems, involved in the conversion of
      nitrite to NO. Increasing knowledge about the nitrite-NO system can contribute to changing
      the clinical practise of diagnostics and treatment of cardiovascular diseases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional urinary sodium excretion</measure>
    <time_frame>One day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nitrite clearance</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrate clearance</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>One day</time_frame>
    <description>Measured by determent renal clearance of 51Cr-EDTA (51-chrome ethylenediaminetetraacetic acid) using constant infusing technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal sodium transport</measure>
    <time_frame>One day</time_frame>
    <description>Proximal sodium transport is estimated by lithium clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free water clearance</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of cyclic guanosine monophosphate (cGMP)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of epithelial sodium channels (ENaC)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of water channels (aquaporin-2)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of renin</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of angiotensin 2</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of aldosterone</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of atrial natriuretic peptide (ANP)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of brain natriuretic peptide (BNP)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of cyclic guanosine monophosphate (cGMP)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of endothelin</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of vasopressin (AVP, ADH)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral (brachial) blood pressure</measure>
    <time_frame>One day</time_frame>
    <description>Measured by oscillometric sphygmomanometer, Omron 705IT, Omron Matsusaka CO. Ltd.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central aortic systolic blood pressure (CASP)</measure>
    <time_frame>One day</time_frame>
    <description>Estimated by tonometric pulse wave analysis. Device: BPro from HealthSTATS International, Singapore</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>40 micrograms sodium nitrite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 micrograms sodium nitrite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>240 micrograms sodium nitrite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continuous 2 hour infusion of sodium chloride, 25 ml/hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium nitrite, 40 micrograms/kg/hour</intervention_name>
    <description>Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour</description>
    <arm_group_label>40 micrograms sodium nitrite</arm_group_label>
    <other_name>NaNO2</other_name>
    <other_name>ATC V03AB08</other_name>
    <other_name>EV substance code: SUB15308MIG</other_name>
    <other_name>CAS15 number: 7632-00-0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium nitrite, 120 micrograms/kg/hour</intervention_name>
    <description>Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour</description>
    <arm_group_label>120 micrograms sodium nitrite</arm_group_label>
    <other_name>NaNO2</other_name>
    <other_name>ATC V03AB08</other_name>
    <other_name>EV substance code: SUB15308MIG</other_name>
    <other_name>CAS15 number: 7632-00-0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium nitrite, 240 micrograms/kg/hour</intervention_name>
    <description>Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour</description>
    <arm_group_label>240 micrograms sodium nitrite</arm_group_label>
    <other_name>NaNO2</other_name>
    <other_name>ATC V03AB08</other_name>
    <other_name>EV substance code: SUB15308MIG</other_name>
    <other_name>CAS15 number: 7632-00-0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Continuous 2 hour infusion of sodium chloride, 25 ml/hour</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 18,5-30 kg/m2

          -  Women must use safe contraception

        Exclusion Criteria:

          -  Tobacco smoking, medicine or substance abuse

          -  Weekly consumption of more than 21 standard drinks of alcohol for men and 14 standard
             drinks of alcohol for women (1 danish standard drink equals 12 grams of alcohol)

          -  Medical treatment in the last 2 weeks except for contraception

          -  Pregnancy or nursing

          -  Diabetes mellitus

          -  estimated glomerular filtration rate (eGFR) &lt; 60 ml/min

          -  neoplasm

          -  clinically significant heart, lung, liver, kidney, metabolic og neurologic disease

          -  clinically significant findings in screening blood samples, urine sample or ECG

          -  Office blood pressure &gt; 140/90 mmHg

          -  Blood donation within 1 month of the first day of investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper N Bech, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medical Research, Regional Hospital Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Chief physician, PhD</investigator_title>
  </responsible_party>
  <keyword>Central blood pressure</keyword>
  <keyword>Peripheral (brachial) blood pressure</keyword>
  <keyword>Renal variables</keyword>
  <keyword>Vasoactive hormones</keyword>
  <keyword>Pharmacology</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

